Global Anti-GFP Nanobody Market Growth 2026-2032
The global Anti-GFP Nanobody market size is predicted to grow from US$ 41.58 million in 2025 to US$ 74.65 million in 2032; it is expected to grow at a CAGR of 9.0% from 2026 to 2032.
Anti-GFP Nanobody refers to a small recombinant single-domain antibody, usually a camelid-derived VHH or sdAb, that specifically binds green fluorescent protein (GFP) and common GFP derivatives. It is mainly used as a research reagent for GFP-tagged protein capture, immunoprecipitation, co-immunoprecipitation, affinity purification, pull-down, ChIP, RIP, fluorescence signal enhancement, immunofluorescence, super-resolution imaging and live-cell or fixed-cell labeling. In this report, the market mainly includes anti-GFP VHH binding proteins, anti-GFP nanobody agarose beads, anti-GFP nanobody magnetic beads, GFP-Trap-type affinity reagents, GFP-Booster-type fluorescent nanobody probes, anti-GFP nanobody affinity gel and customized anti-GFP nanobody conjugates. The 2025 benchmark ASP is US$250 / unit, sales volume is 170.00k units, and average gross margin is 72%. The upstream industry chain includes GFP antigen, alpaca / llama immunization resources, VHH libraries, phage display platforms, recombinant expression systems, E. coli / mammalian expression media, affinity purification resins, fluorescent dyes, biotin, HRP, agarose beads, magnetic beads, linkers, buffers and stabilizers. The midstream includes nanobody discovery, sequence screening, recombinant expression, purification, conjugation, bead coupling, affinity testing, specificity validation, IP / Co-IP validation, imaging validation, lyophilization or liquid formulation, packaging and quality control. The downstream includes universities, life-science research institutes, biotechnology companies, pharmaceutical R&D labs, proteomics laboratories, imaging core facilities, cell biology labs, antibody reagent distributors and contract research organizations.
Anti-GFP Nanobody is a small but high-value life-science reagent segment. GFP remains one of the most widely used protein tags and fluorescent reporters in molecular biology, cell biology, live-cell imaging and protein interaction studies. Compared with conventional anti-GFP IgG antibodies, anti-GFP nanobodies are much smaller, recombinant, stable and easier to conjugate to beads, dyes, enzymes or other functional groups. This makes them especially attractive for GFP-fusion protein pull-down, Co-IP, proteomics, super-resolution microscopy and signal amplification. Demand is driven by continued use of GFP-tagged cell lines, CRISPR knock-in fluorescent tags, live-cell imaging, protein interaction mapping, IP-MS workflows, high-resolution microscopy and faster magnetic bead-based sample preparation. Market growth is also supported by premium formatted products such as GFP-Trap beads, GFP-Booster fluorescent probes, affinity gels and ready-to-use IP kits. However, the market is constrained by its niche research-only nature, competition from conventional anti-GFP antibodies, availability of homemade GFP nanobody beads, academic protocols, price sensitivity in university labs and substitution by other epitope tags such as FLAG, HA, Myc, His, HaloTag and SNAP-tag. Future competition will focus on higher binding capacity beads, lower nonspecific background, broader recognition of GFP variants, brighter dye conjugates, super-resolution imaging compatibility, automation-ready magnetic formats, multiplex fluorescent nanobodies and custom conjugation services.
LP Information, Inc. (LPI) ' newest research report, the “Anti-GFP Nanobody Industry Forecast” looks at past sales and reviews total world Anti-GFP Nanobody sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-GFP Nanobody sales for 2026 through 2032. With Anti-GFP Nanobody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-GFP Nanobody industry.
This Insight Report provides a comprehensive analysis of the global Anti-GFP Nanobody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-GFP Nanobody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-GFP Nanobody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-GFP Nanobody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-GFP Nanobody.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-GFP Nanobody market by product type, application, key manufacturers and key regions and countries.
Anti-GFP Nanobody refers to a small recombinant single-domain antibody, usually a camelid-derived VHH or sdAb, that specifically binds green fluorescent protein (GFP) and common GFP derivatives. It is mainly used as a research reagent for GFP-tagged protein capture, immunoprecipitation, co-immunoprecipitation, affinity purification, pull-down, ChIP, RIP, fluorescence signal enhancement, immunofluorescence, super-resolution imaging and live-cell or fixed-cell labeling. In this report, the market mainly includes anti-GFP VHH binding proteins, anti-GFP nanobody agarose beads, anti-GFP nanobody magnetic beads, GFP-Trap-type affinity reagents, GFP-Booster-type fluorescent nanobody probes, anti-GFP nanobody affinity gel and customized anti-GFP nanobody conjugates. The 2025 benchmark ASP is US$250 / unit, sales volume is 170.00k units, and average gross margin is 72%. The upstream industry chain includes GFP antigen, alpaca / llama immunization resources, VHH libraries, phage display platforms, recombinant expression systems, E. coli / mammalian expression media, affinity purification resins, fluorescent dyes, biotin, HRP, agarose beads, magnetic beads, linkers, buffers and stabilizers. The midstream includes nanobody discovery, sequence screening, recombinant expression, purification, conjugation, bead coupling, affinity testing, specificity validation, IP / Co-IP validation, imaging validation, lyophilization or liquid formulation, packaging and quality control. The downstream includes universities, life-science research institutes, biotechnology companies, pharmaceutical R&D labs, proteomics laboratories, imaging core facilities, cell biology labs, antibody reagent distributors and contract research organizations.
Anti-GFP Nanobody is a small but high-value life-science reagent segment. GFP remains one of the most widely used protein tags and fluorescent reporters in molecular biology, cell biology, live-cell imaging and protein interaction studies. Compared with conventional anti-GFP IgG antibodies, anti-GFP nanobodies are much smaller, recombinant, stable and easier to conjugate to beads, dyes, enzymes or other functional groups. This makes them especially attractive for GFP-fusion protein pull-down, Co-IP, proteomics, super-resolution microscopy and signal amplification. Demand is driven by continued use of GFP-tagged cell lines, CRISPR knock-in fluorescent tags, live-cell imaging, protein interaction mapping, IP-MS workflows, high-resolution microscopy and faster magnetic bead-based sample preparation. Market growth is also supported by premium formatted products such as GFP-Trap beads, GFP-Booster fluorescent probes, affinity gels and ready-to-use IP kits. However, the market is constrained by its niche research-only nature, competition from conventional anti-GFP antibodies, availability of homemade GFP nanobody beads, academic protocols, price sensitivity in university labs and substitution by other epitope tags such as FLAG, HA, Myc, His, HaloTag and SNAP-tag. Future competition will focus on higher binding capacity beads, lower nonspecific background, broader recognition of GFP variants, brighter dye conjugates, super-resolution imaging compatibility, automation-ready magnetic formats, multiplex fluorescent nanobodies and custom conjugation services.
LP Information, Inc. (LPI) ' newest research report, the “Anti-GFP Nanobody Industry Forecast” looks at past sales and reviews total world Anti-GFP Nanobody sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-GFP Nanobody sales for 2026 through 2032. With Anti-GFP Nanobody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-GFP Nanobody industry.
This Insight Report provides a comprehensive analysis of the global Anti-GFP Nanobody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-GFP Nanobody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-GFP Nanobody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-GFP Nanobody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-GFP Nanobody.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-GFP Nanobody market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monovalent Nanobodies
- Bivalent Nanobodies
- Bispecific Nanobodies
- Multivalent Nanobodies
- Fused Nanobodies
Segmentation by Reagent Format:
- VHH Binding Protein
- Affinity Gel / Resin
- Magnetic Bead Reagent
- Ready-to-Use IP Kit
Segmentation by Conjugation Type:
- Biotin-Conjugated Type
- Fluorophore-Conjugated Type
- HRP-Conjugated Type
- Bead-Coupled Type
Segmentation by Application:
- University Laboratory
- Research Institute
- Biotechnology Company
- Pharmaceutical R&D Lab
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Proteintech / ChromoTek
- Proteintech / ChromoTek GFP-Booster
- NanoTag Biotechnologies
- NanoTag FluoTag-X4 anti-GFP
- BioLegend
- ABclonal Agarose Beads
- Yeasen Biotechnology
- AntibodySystem
- Antibodies.com
- MBL Life Science
- Cosmo Bio
- Bulldog Bio
- System Biosciences
- Sino Biological
- CUSABIO / Wuhan Huamei Biotech
- MSE Supplies
- KTSM Life Science
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Anti-GFP Nanobody market?
- What factors are driving Anti-GFP Nanobody market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Anti-GFP Nanobody market opportunities vary by end market size?
- How does Anti-GFP Nanobody break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-GFP Nanobody Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Anti-GFP Nanobody by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Anti-GFP Nanobody by Country/Region, 2021, 2025 & 2032
2.2 Anti-GFP Nanobody Segment by Type
2.2.1 Monovalent Nanobodies
2.2.2 Bivalent Nanobodies
2.2.3 Bispecific Nanobodies
2.2.4 Multivalent Nanobodies
2.2.5 Fused Nanobodies
2.2.6 Anti-GFP Nanobody Sales by Type
2.2.6.1 Global Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
2.2.6.2 Global Anti-GFP Nanobody Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Anti-GFP Nanobody Sale Price by Type (2021-2026)
2.3 Anti-GFP Nanobody Segment by Reagent Format
2.3.1 VHH Binding Protein
2.3.2 Affinity Gel / Resin
2.3.3 Magnetic Bead Reagent
2.3.4 Ready-to-Use IP Kit
2.3.5 Anti-GFP Nanobody Sales by Reagent Format
2.3.5.1 Global Anti-GFP Nanobody Sales Market Share by Reagent Format (2021-2026)
2.3.5.2 Global Anti-GFP Nanobody Revenue and Market Share by Reagent Format (2021-2026)
2.3.5.3 Global Anti-GFP Nanobody Sale Price by Reagent Format (2021-2026)
2.4 Anti-GFP Nanobody Segment by Conjugation Type
2.4.1 Biotin-Conjugated Type
2.4.2 Fluorophore-Conjugated Type
2.4.3 HRP-Conjugated Type
2.4.4 Bead-Coupled Type
2.4.5 Anti-GFP Nanobody Sales by Conjugation Type
2.4.5.1 Global Anti-GFP Nanobody Sales Market Share by Conjugation Type (2021-2026)
2.4.5.2 Global Anti-GFP Nanobody Revenue and Market Share by Conjugation Type (2021-2026)
2.4.5.3 Global Anti-GFP Nanobody Sale Price by Conjugation Type (2021-2026)
2.5 Anti-GFP Nanobody Segment by Application
2.5.1 University Laboratory
2.5.2 Research Institute
2.5.3 Biotechnology Company
2.5.4 Pharmaceutical R&D Lab
2.5.5 Anti-GFP Nanobody Sales by Application
2.5.5.1 Global Anti-GFP Nanobody Sale Market Share by Application (2021-2026)
2.5.5.2 Global Anti-GFP Nanobody Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Anti-GFP Nanobody Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Anti-GFP Nanobody Breakdown Data by Company
3.1.1 Global Anti-GFP Nanobody Annual Sales by Company (2021-2026)
3.1.2 Global Anti-GFP Nanobody Sales Market Share by Company (2021-2026)
3.2 Global Anti-GFP Nanobody Annual Revenue by Company (2021-2026)
3.2.1 Global Anti-GFP Nanobody Revenue by Company (2021-2026)
3.2.2 Global Anti-GFP Nanobody Revenue Market Share by Company (2021-2026)
3.3 Global Anti-GFP Nanobody Sale Price by Company
3.4 Key Manufacturers Anti-GFP Nanobody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-GFP Nanobody Product Location Distribution
3.4.2 Players Anti-GFP Nanobody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-GFP NANOBODY BY GEOGRAPHIC REGION
4.1 World Historic Anti-GFP Nanobody Market Size by Geographic Region (2021-2026)
4.1.1 Global Anti-GFP Nanobody Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Anti-GFP Nanobody Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Anti-GFP Nanobody Market Size by Country/Region (2021-2026)
4.2.1 Global Anti-GFP Nanobody Annual Sales by Country/Region (2021-2026)
4.2.2 Global Anti-GFP Nanobody Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-GFP Nanobody Sales Growth
4.4 APAC Anti-GFP Nanobody Sales Growth
4.5 Europe Anti-GFP Nanobody Sales Growth
4.6 Middle East & Africa Anti-GFP Nanobody Sales Growth
5 AMERICAS
5.1 Americas Anti-GFP Nanobody Sales by Country
5.1.1 Americas Anti-GFP Nanobody Sales by Country (2021-2026)
5.1.2 Americas Anti-GFP Nanobody Revenue by Country (2021-2026)
5.2 Americas Anti-GFP Nanobody Sales by Type (2021-2026)
5.3 Americas Anti-GFP Nanobody Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-GFP Nanobody Sales by Region
6.1.1 APAC Anti-GFP Nanobody Sales by Region (2021-2026)
6.1.2 APAC Anti-GFP Nanobody Revenue by Region (2021-2026)
6.2 APAC Anti-GFP Nanobody Sales by Type (2021-2026)
6.3 APAC Anti-GFP Nanobody Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-GFP Nanobody by Country
7.1.1 Europe Anti-GFP Nanobody Sales by Country (2021-2026)
7.1.2 Europe Anti-GFP Nanobody Revenue by Country (2021-2026)
7.2 Europe Anti-GFP Nanobody Sales by Type (2021-2026)
7.3 Europe Anti-GFP Nanobody Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-GFP Nanobody by Country
8.1.1 Middle East & Africa Anti-GFP Nanobody Sales by Country (2021-2026)
8.1.2 Middle East & Africa Anti-GFP Nanobody Revenue by Country (2021-2026)
8.2 Middle East & Africa Anti-GFP Nanobody Sales by Type (2021-2026)
8.3 Middle East & Africa Anti-GFP Nanobody Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-GFP Nanobody
10.3 Manufacturing Process Analysis of Anti-GFP Nanobody
10.4 Industry Chain Structure of Anti-GFP Nanobody
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-GFP Nanobody Distributors
11.3 Anti-GFP Nanobody Customer
12 WORLD FORECAST REVIEW FOR ANTI-GFP NANOBODY BY GEOGRAPHIC REGION
12.1 Global Anti-GFP Nanobody Market Size Forecast by Region
12.1.1 Global Anti-GFP Nanobody Forecast by Region (2027-2032)
12.1.2 Global Anti-GFP Nanobody Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Anti-GFP Nanobody Forecast by Type (2027-2032)
12.7 Global Anti-GFP Nanobody Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Proteintech / ChromoTek
13.1.1 Proteintech / ChromoTek Company Information
13.1.2 Proteintech / ChromoTek Anti-GFP Nanobody Product Portfolios and Specifications
13.1.3 Proteintech / ChromoTek Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Proteintech / ChromoTek Main Business Overview
13.1.5 Proteintech / ChromoTek Latest Developments
13.2 Proteintech / ChromoTek GFP-Booster
13.2.1 Proteintech / ChromoTek GFP-Booster Company Information
13.2.2 Proteintech / ChromoTek GFP-Booster Anti-GFP Nanobody Product Portfolios and Specifications
13.2.3 Proteintech / ChromoTek GFP-Booster Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Proteintech / ChromoTek GFP-Booster Main Business Overview
13.2.5 Proteintech / ChromoTek GFP-Booster Latest Developments
13.3 NanoTag Biotechnologies
13.3.1 NanoTag Biotechnologies Company Information
13.3.2 NanoTag Biotechnologies Anti-GFP Nanobody Product Portfolios and Specifications
13.3.3 NanoTag Biotechnologies Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 NanoTag Biotechnologies Main Business Overview
13.3.5 NanoTag Biotechnologies Latest Developments
13.4 NanoTag FluoTag-X4 anti-GFP
13.4.1 NanoTag FluoTag-X4 anti-GFP Company Information
13.4.2 NanoTag FluoTag-X4 anti-GFP Anti-GFP Nanobody Product Portfolios and Specifications
13.4.3 NanoTag FluoTag-X4 anti-GFP Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 NanoTag FluoTag-X4 anti-GFP Main Business Overview
13.4.5 NanoTag FluoTag-X4 anti-GFP Latest Developments
13.5 BioLegend
13.5.1 BioLegend Company Information
13.5.2 BioLegend Anti-GFP Nanobody Product Portfolios and Specifications
13.5.3 BioLegend Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 BioLegend Main Business Overview
13.5.5 BioLegend Latest Developments
13.6 ABclonal Agarose Beads
13.6.1 ABclonal Agarose Beads Company Information
13.6.2 ABclonal Agarose Beads Anti-GFP Nanobody Product Portfolios and Specifications
13.6.3 ABclonal Agarose Beads Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 ABclonal Agarose Beads Main Business Overview
13.6.5 ABclonal Agarose Beads Latest Developments
13.7 Yeasen Biotechnology
13.7.1 Yeasen Biotechnology Company Information
13.7.2 Yeasen Biotechnology Anti-GFP Nanobody Product Portfolios and Specifications
13.7.3 Yeasen Biotechnology Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Yeasen Biotechnology Main Business Overview
13.7.5 Yeasen Biotechnology Latest Developments
13.8 AntibodySystem
13.8.1 AntibodySystem Company Information
13.8.2 AntibodySystem Anti-GFP Nanobody Product Portfolios and Specifications
13.8.3 AntibodySystem Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 AntibodySystem Main Business Overview
13.8.5 AntibodySystem Latest Developments
13.9 Antibodies.com
13.9.1 Antibodies.com Company Information
13.9.2 Antibodies.com Anti-GFP Nanobody Product Portfolios and Specifications
13.9.3 Antibodies.com Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Antibodies.com Main Business Overview
13.9.5 Antibodies.com Latest Developments
13.10 MBL Life Science
13.10.1 MBL Life Science Company Information
13.10.2 MBL Life Science Anti-GFP Nanobody Product Portfolios and Specifications
13.10.3 MBL Life Science Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 MBL Life Science Main Business Overview
13.10.5 MBL Life Science Latest Developments
13.11 Cosmo Bio
13.11.1 Cosmo Bio Company Information
13.11.2 Cosmo Bio Anti-GFP Nanobody Product Portfolios and Specifications
13.11.3 Cosmo Bio Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Cosmo Bio Main Business Overview
13.11.5 Cosmo Bio Latest Developments
13.12 Bulldog Bio
13.12.1 Bulldog Bio Company Information
13.12.2 Bulldog Bio Anti-GFP Nanobody Product Portfolios and Specifications
13.12.3 Bulldog Bio Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Bulldog Bio Main Business Overview
13.12.5 Bulldog Bio Latest Developments
13.13 System Biosciences
13.13.1 System Biosciences Company Information
13.13.2 System Biosciences Anti-GFP Nanobody Product Portfolios and Specifications
13.13.3 System Biosciences Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 System Biosciences Main Business Overview
13.13.5 System Biosciences Latest Developments
13.14 Sino Biological
13.14.1 Sino Biological Company Information
13.14.2 Sino Biological Anti-GFP Nanobody Product Portfolios and Specifications
13.14.3 Sino Biological Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sino Biological Main Business Overview
13.14.5 Sino Biological Latest Developments
13.15 CUSABIO / Wuhan Huamei Biotech
13.15.1 CUSABIO / Wuhan Huamei Biotech Company Information
13.15.2 CUSABIO / Wuhan Huamei Biotech Anti-GFP Nanobody Product Portfolios and Specifications
13.15.3 CUSABIO / Wuhan Huamei Biotech Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 CUSABIO / Wuhan Huamei Biotech Main Business Overview
13.15.5 CUSABIO / Wuhan Huamei Biotech Latest Developments
13.16 MSE Supplies
13.16.1 MSE Supplies Company Information
13.16.2 MSE Supplies Anti-GFP Nanobody Product Portfolios and Specifications
13.16.3 MSE Supplies Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 MSE Supplies Main Business Overview
13.16.5 MSE Supplies Latest Developments
13.17 KTSM Life Science
13.17.1 KTSM Life Science Company Information
13.17.2 KTSM Life Science Anti-GFP Nanobody Product Portfolios and Specifications
13.17.3 KTSM Life Science Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 KTSM Life Science Main Business Overview
13.17.5 KTSM Life Science Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-GFP Nanobody Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Anti-GFP Nanobody by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Anti-GFP Nanobody by Country/Region, 2021, 2025 & 2032
2.2 Anti-GFP Nanobody Segment by Type
2.2.1 Monovalent Nanobodies
2.2.2 Bivalent Nanobodies
2.2.3 Bispecific Nanobodies
2.2.4 Multivalent Nanobodies
2.2.5 Fused Nanobodies
2.2.6 Anti-GFP Nanobody Sales by Type
2.2.6.1 Global Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
2.2.6.2 Global Anti-GFP Nanobody Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Anti-GFP Nanobody Sale Price by Type (2021-2026)
2.3 Anti-GFP Nanobody Segment by Reagent Format
2.3.1 VHH Binding Protein
2.3.2 Affinity Gel / Resin
2.3.3 Magnetic Bead Reagent
2.3.4 Ready-to-Use IP Kit
2.3.5 Anti-GFP Nanobody Sales by Reagent Format
2.3.5.1 Global Anti-GFP Nanobody Sales Market Share by Reagent Format (2021-2026)
2.3.5.2 Global Anti-GFP Nanobody Revenue and Market Share by Reagent Format (2021-2026)
2.3.5.3 Global Anti-GFP Nanobody Sale Price by Reagent Format (2021-2026)
2.4 Anti-GFP Nanobody Segment by Conjugation Type
2.4.1 Biotin-Conjugated Type
2.4.2 Fluorophore-Conjugated Type
2.4.3 HRP-Conjugated Type
2.4.4 Bead-Coupled Type
2.4.5 Anti-GFP Nanobody Sales by Conjugation Type
2.4.5.1 Global Anti-GFP Nanobody Sales Market Share by Conjugation Type (2021-2026)
2.4.5.2 Global Anti-GFP Nanobody Revenue and Market Share by Conjugation Type (2021-2026)
2.4.5.3 Global Anti-GFP Nanobody Sale Price by Conjugation Type (2021-2026)
2.5 Anti-GFP Nanobody Segment by Application
2.5.1 University Laboratory
2.5.2 Research Institute
2.5.3 Biotechnology Company
2.5.4 Pharmaceutical R&D Lab
2.5.5 Anti-GFP Nanobody Sales by Application
2.5.5.1 Global Anti-GFP Nanobody Sale Market Share by Application (2021-2026)
2.5.5.2 Global Anti-GFP Nanobody Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Anti-GFP Nanobody Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Anti-GFP Nanobody Breakdown Data by Company
3.1.1 Global Anti-GFP Nanobody Annual Sales by Company (2021-2026)
3.1.2 Global Anti-GFP Nanobody Sales Market Share by Company (2021-2026)
3.2 Global Anti-GFP Nanobody Annual Revenue by Company (2021-2026)
3.2.1 Global Anti-GFP Nanobody Revenue by Company (2021-2026)
3.2.2 Global Anti-GFP Nanobody Revenue Market Share by Company (2021-2026)
3.3 Global Anti-GFP Nanobody Sale Price by Company
3.4 Key Manufacturers Anti-GFP Nanobody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-GFP Nanobody Product Location Distribution
3.4.2 Players Anti-GFP Nanobody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-GFP NANOBODY BY GEOGRAPHIC REGION
4.1 World Historic Anti-GFP Nanobody Market Size by Geographic Region (2021-2026)
4.1.1 Global Anti-GFP Nanobody Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Anti-GFP Nanobody Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Anti-GFP Nanobody Market Size by Country/Region (2021-2026)
4.2.1 Global Anti-GFP Nanobody Annual Sales by Country/Region (2021-2026)
4.2.2 Global Anti-GFP Nanobody Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-GFP Nanobody Sales Growth
4.4 APAC Anti-GFP Nanobody Sales Growth
4.5 Europe Anti-GFP Nanobody Sales Growth
4.6 Middle East & Africa Anti-GFP Nanobody Sales Growth
5 AMERICAS
5.1 Americas Anti-GFP Nanobody Sales by Country
5.1.1 Americas Anti-GFP Nanobody Sales by Country (2021-2026)
5.1.2 Americas Anti-GFP Nanobody Revenue by Country (2021-2026)
5.2 Americas Anti-GFP Nanobody Sales by Type (2021-2026)
5.3 Americas Anti-GFP Nanobody Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-GFP Nanobody Sales by Region
6.1.1 APAC Anti-GFP Nanobody Sales by Region (2021-2026)
6.1.2 APAC Anti-GFP Nanobody Revenue by Region (2021-2026)
6.2 APAC Anti-GFP Nanobody Sales by Type (2021-2026)
6.3 APAC Anti-GFP Nanobody Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-GFP Nanobody by Country
7.1.1 Europe Anti-GFP Nanobody Sales by Country (2021-2026)
7.1.2 Europe Anti-GFP Nanobody Revenue by Country (2021-2026)
7.2 Europe Anti-GFP Nanobody Sales by Type (2021-2026)
7.3 Europe Anti-GFP Nanobody Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-GFP Nanobody by Country
8.1.1 Middle East & Africa Anti-GFP Nanobody Sales by Country (2021-2026)
8.1.2 Middle East & Africa Anti-GFP Nanobody Revenue by Country (2021-2026)
8.2 Middle East & Africa Anti-GFP Nanobody Sales by Type (2021-2026)
8.3 Middle East & Africa Anti-GFP Nanobody Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-GFP Nanobody
10.3 Manufacturing Process Analysis of Anti-GFP Nanobody
10.4 Industry Chain Structure of Anti-GFP Nanobody
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-GFP Nanobody Distributors
11.3 Anti-GFP Nanobody Customer
12 WORLD FORECAST REVIEW FOR ANTI-GFP NANOBODY BY GEOGRAPHIC REGION
12.1 Global Anti-GFP Nanobody Market Size Forecast by Region
12.1.1 Global Anti-GFP Nanobody Forecast by Region (2027-2032)
12.1.2 Global Anti-GFP Nanobody Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Anti-GFP Nanobody Forecast by Type (2027-2032)
12.7 Global Anti-GFP Nanobody Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Proteintech / ChromoTek
13.1.1 Proteintech / ChromoTek Company Information
13.1.2 Proteintech / ChromoTek Anti-GFP Nanobody Product Portfolios and Specifications
13.1.3 Proteintech / ChromoTek Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Proteintech / ChromoTek Main Business Overview
13.1.5 Proteintech / ChromoTek Latest Developments
13.2 Proteintech / ChromoTek GFP-Booster
13.2.1 Proteintech / ChromoTek GFP-Booster Company Information
13.2.2 Proteintech / ChromoTek GFP-Booster Anti-GFP Nanobody Product Portfolios and Specifications
13.2.3 Proteintech / ChromoTek GFP-Booster Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Proteintech / ChromoTek GFP-Booster Main Business Overview
13.2.5 Proteintech / ChromoTek GFP-Booster Latest Developments
13.3 NanoTag Biotechnologies
13.3.1 NanoTag Biotechnologies Company Information
13.3.2 NanoTag Biotechnologies Anti-GFP Nanobody Product Portfolios and Specifications
13.3.3 NanoTag Biotechnologies Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 NanoTag Biotechnologies Main Business Overview
13.3.5 NanoTag Biotechnologies Latest Developments
13.4 NanoTag FluoTag-X4 anti-GFP
13.4.1 NanoTag FluoTag-X4 anti-GFP Company Information
13.4.2 NanoTag FluoTag-X4 anti-GFP Anti-GFP Nanobody Product Portfolios and Specifications
13.4.3 NanoTag FluoTag-X4 anti-GFP Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 NanoTag FluoTag-X4 anti-GFP Main Business Overview
13.4.5 NanoTag FluoTag-X4 anti-GFP Latest Developments
13.5 BioLegend
13.5.1 BioLegend Company Information
13.5.2 BioLegend Anti-GFP Nanobody Product Portfolios and Specifications
13.5.3 BioLegend Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 BioLegend Main Business Overview
13.5.5 BioLegend Latest Developments
13.6 ABclonal Agarose Beads
13.6.1 ABclonal Agarose Beads Company Information
13.6.2 ABclonal Agarose Beads Anti-GFP Nanobody Product Portfolios and Specifications
13.6.3 ABclonal Agarose Beads Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 ABclonal Agarose Beads Main Business Overview
13.6.5 ABclonal Agarose Beads Latest Developments
13.7 Yeasen Biotechnology
13.7.1 Yeasen Biotechnology Company Information
13.7.2 Yeasen Biotechnology Anti-GFP Nanobody Product Portfolios and Specifications
13.7.3 Yeasen Biotechnology Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Yeasen Biotechnology Main Business Overview
13.7.5 Yeasen Biotechnology Latest Developments
13.8 AntibodySystem
13.8.1 AntibodySystem Company Information
13.8.2 AntibodySystem Anti-GFP Nanobody Product Portfolios and Specifications
13.8.3 AntibodySystem Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 AntibodySystem Main Business Overview
13.8.5 AntibodySystem Latest Developments
13.9 Antibodies.com
13.9.1 Antibodies.com Company Information
13.9.2 Antibodies.com Anti-GFP Nanobody Product Portfolios and Specifications
13.9.3 Antibodies.com Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Antibodies.com Main Business Overview
13.9.5 Antibodies.com Latest Developments
13.10 MBL Life Science
13.10.1 MBL Life Science Company Information
13.10.2 MBL Life Science Anti-GFP Nanobody Product Portfolios and Specifications
13.10.3 MBL Life Science Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 MBL Life Science Main Business Overview
13.10.5 MBL Life Science Latest Developments
13.11 Cosmo Bio
13.11.1 Cosmo Bio Company Information
13.11.2 Cosmo Bio Anti-GFP Nanobody Product Portfolios and Specifications
13.11.3 Cosmo Bio Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Cosmo Bio Main Business Overview
13.11.5 Cosmo Bio Latest Developments
13.12 Bulldog Bio
13.12.1 Bulldog Bio Company Information
13.12.2 Bulldog Bio Anti-GFP Nanobody Product Portfolios and Specifications
13.12.3 Bulldog Bio Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Bulldog Bio Main Business Overview
13.12.5 Bulldog Bio Latest Developments
13.13 System Biosciences
13.13.1 System Biosciences Company Information
13.13.2 System Biosciences Anti-GFP Nanobody Product Portfolios and Specifications
13.13.3 System Biosciences Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 System Biosciences Main Business Overview
13.13.5 System Biosciences Latest Developments
13.14 Sino Biological
13.14.1 Sino Biological Company Information
13.14.2 Sino Biological Anti-GFP Nanobody Product Portfolios and Specifications
13.14.3 Sino Biological Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sino Biological Main Business Overview
13.14.5 Sino Biological Latest Developments
13.15 CUSABIO / Wuhan Huamei Biotech
13.15.1 CUSABIO / Wuhan Huamei Biotech Company Information
13.15.2 CUSABIO / Wuhan Huamei Biotech Anti-GFP Nanobody Product Portfolios and Specifications
13.15.3 CUSABIO / Wuhan Huamei Biotech Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 CUSABIO / Wuhan Huamei Biotech Main Business Overview
13.15.5 CUSABIO / Wuhan Huamei Biotech Latest Developments
13.16 MSE Supplies
13.16.1 MSE Supplies Company Information
13.16.2 MSE Supplies Anti-GFP Nanobody Product Portfolios and Specifications
13.16.3 MSE Supplies Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 MSE Supplies Main Business Overview
13.16.5 MSE Supplies Latest Developments
13.17 KTSM Life Science
13.17.1 KTSM Life Science Company Information
13.17.2 KTSM Life Science Anti-GFP Nanobody Product Portfolios and Specifications
13.17.3 KTSM Life Science Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 KTSM Life Science Main Business Overview
13.17.5 KTSM Life Science Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anti-GFP Nanobody Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Anti-GFP Nanobody Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monovalent Nanobodies
Table 4. Major Players of Bivalent Nanobodies
Table 5. Major Players of Bispecific Nanobodies
Table 6. Major Players of Multivalent Nanobodies
Table 7. Major Players of Fused Nanobodies
Table 8. Global Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 9. Global Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Table 10. Global Anti-GFP Nanobody Revenue by Type (2021-2026) & ($ million)
Table 11. Global Anti-GFP Nanobody Revenue Market Share by Type (2021-2026)
Table 12. Global Anti-GFP Nanobody Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Major Players of VHH Binding Protein
Table 14. Major Players of Affinity Gel / Resin
Table 15. Major Players of Magnetic Bead Reagent
Table 16. Major Players of Ready-to-Use IP Kit
Table 17. Global Anti-GFP Nanobody Sales by Reagent Format (2021-2026) & (K Units)
Table 18. Global Anti-GFP Nanobody Sales Market Share by Reagent Format (2021-2026)
Table 19. Global Anti-GFP Nanobody Revenue by Reagent Format (2021-2026) & ($ million)
Table 20. Global Anti-GFP Nanobody Revenue Market Share by Reagent Format (2021-2026)
Table 21. Global Anti-GFP Nanobody Sale Price by Reagent Format (2021-2026) & (US$/Unit)
Table 22. Major Players of Biotin-Conjugated Type
Table 23. Major Players of Fluorophore-Conjugated Type
Table 24. Major Players of HRP-Conjugated Type
Table 25. Major Players of Bead-Coupled Type
Table 26. Global Anti-GFP Nanobody Sales by Conjugation Type (2021-2026) & (K Units)
Table 27. Global Anti-GFP Nanobody Sales Market Share by Conjugation Type (2021-2026)
Table 28. Global Anti-GFP Nanobody Revenue by Conjugation Type (2021-2026) & ($ million)
Table 29. Global Anti-GFP Nanobody Revenue Market Share by Conjugation Type (2021-2026)
Table 30. Global Anti-GFP Nanobody Sale Price by Conjugation Type (2021-2026) & (US$/Unit)
Table 31. Global Anti-GFP Nanobody Sale by Application (2021-2026) & (K Units)
Table 32. Global Anti-GFP Nanobody Sale Market Share by Application (2021-2026)
Table 33. Global Anti-GFP Nanobody Revenue by Application (2021-2026) & ($ million)
Table 34. Global Anti-GFP Nanobody Revenue Market Share by Application (2021-2026)
Table 35. Global Anti-GFP Nanobody Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Anti-GFP Nanobody Sales by Company (2021-2026) & (K Units)
Table 37. Global Anti-GFP Nanobody Sales Market Share by Company (2021-2026)
Table 38. Global Anti-GFP Nanobody Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Anti-GFP Nanobody Revenue Market Share by Company (2021-2026)
Table 40. Global Anti-GFP Nanobody Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Anti-GFP Nanobody Producing Area Distribution and Sales Area
Table 42. Players Anti-GFP Nanobody Products Offered
Table 43. Anti-GFP Nanobody Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Anti-GFP Nanobody Sales by Geographic Region (2021-2026) & (K Units)
Table 47. Global Anti-GFP Nanobody Sales Market Share Geographic Region (2021-2026)
Table 48. Global Anti-GFP Nanobody Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Anti-GFP Nanobody Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Anti-GFP Nanobody Sales by Country/Region (2021-2026) & (K Units)
Table 51. Global Anti-GFP Nanobody Sales Market Share by Country/Region (2021-2026)
Table 52. Global Anti-GFP Nanobody Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Anti-GFP Nanobody Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Anti-GFP Nanobody Sales by Country (2021-2026) & (K Units)
Table 55. Americas Anti-GFP Nanobody Sales Market Share by Country (2021-2026)
Table 56. Americas Anti-GFP Nanobody Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 58. Americas Anti-GFP Nanobody Sales by Application (2021-2026) & (K Units)
Table 59. APAC Anti-GFP Nanobody Sales by Region (2021-2026) & (K Units)
Table 60. APAC Anti-GFP Nanobody Sales Market Share by Region (2021-2026)
Table 61. APAC Anti-GFP Nanobody Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 63. APAC Anti-GFP Nanobody Sales by Application (2021-2026) & (K Units)
Table 64. Europe Anti-GFP Nanobody Sales by Country (2021-2026) & (K Units)
Table 65. Europe Anti-GFP Nanobody Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 67. Europe Anti-GFP Nanobody Sales by Application (2021-2026) & (K Units)
Table 68. Middle East & Africa Anti-GFP Nanobody Sales by Country (2021-2026) & (K Units)
Table 69. Middle East & Africa Anti-GFP Nanobody Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 71. Middle East & Africa Anti-GFP Nanobody Sales by Application (2021-2026) & (K Units)
Table 72. Key Market Drivers & Growth Opportunities of Anti-GFP Nanobody
Table 73. Key Market Challenges & Risks of Anti-GFP Nanobody
Table 74. Key Industry Trends of Anti-GFP Nanobody
Table 75. Anti-GFP Nanobody Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Anti-GFP Nanobody Distributors List
Table 78. Anti-GFP Nanobody Customer List
Table 79. Global Anti-GFP Nanobody Sales Forecast by Region (2027-2032) & (K Units)
Table 80. Global Anti-GFP Nanobody Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Anti-GFP Nanobody Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Americas Anti-GFP Nanobody Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Anti-GFP Nanobody Sales Forecast by Region (2027-2032) & (K Units)
Table 84. APAC Anti-GFP Nanobody Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Anti-GFP Nanobody Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Europe Anti-GFP Nanobody Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Anti-GFP Nanobody Sales Forecast by Country (2027-2032) & (K Units)
Table 88. Middle East & Africa Anti-GFP Nanobody Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Anti-GFP Nanobody Sales Forecast by Type (2027-2032) & (K Units)
Table 90. Global Anti-GFP Nanobody Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Anti-GFP Nanobody Sales Forecast by Application (2027-2032) & (K Units)
Table 92. Global Anti-GFP Nanobody Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Proteintech / ChromoTek Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 94. Proteintech / ChromoTek Anti-GFP Nanobody Product Portfolios and Specifications
Table 95. Proteintech / ChromoTek Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Proteintech / ChromoTek Main Business
Table 97. Proteintech / ChromoTek Latest Developments
Table 98. Proteintech / ChromoTek GFP-Booster Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 99. Proteintech / ChromoTek GFP-Booster Anti-GFP Nanobody Product Portfolios and Specifications
Table 100. Proteintech / ChromoTek GFP-Booster Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Proteintech / ChromoTek GFP-Booster Main Business
Table 102. Proteintech / ChromoTek GFP-Booster Latest Developments
Table 103. NanoTag Biotechnologies Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 104. NanoTag Biotechnologies Anti-GFP Nanobody Product Portfolios and Specifications
Table 105. NanoTag Biotechnologies Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. NanoTag Biotechnologies Main Business
Table 107. NanoTag Biotechnologies Latest Developments
Table 108. NanoTag FluoTag-X4 anti-GFP Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 109. NanoTag FluoTag-X4 anti-GFP Anti-GFP Nanobody Product Portfolios and Specifications
Table 110. NanoTag FluoTag-X4 anti-GFP Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. NanoTag FluoTag-X4 anti-GFP Main Business
Table 112. NanoTag FluoTag-X4 anti-GFP Latest Developments
Table 113. BioLegend Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 114. BioLegend Anti-GFP Nanobody Product Portfolios and Specifications
Table 115. BioLegend Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. BioLegend Main Business
Table 117. BioLegend Latest Developments
Table 118. ABclonal Agarose Beads Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 119. ABclonal Agarose Beads Anti-GFP Nanobody Product Portfolios and Specifications
Table 120. ABclonal Agarose Beads Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. ABclonal Agarose Beads Main Business
Table 122. ABclonal Agarose Beads Latest Developments
Table 123. Yeasen Biotechnology Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 124. Yeasen Biotechnology Anti-GFP Nanobody Product Portfolios and Specifications
Table 125. Yeasen Biotechnology Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Yeasen Biotechnology Main Business
Table 127. Yeasen Biotechnology Latest Developments
Table 128. AntibodySystem Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 129. AntibodySystem Anti-GFP Nanobody Product Portfolios and Specifications
Table 130. AntibodySystem Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. AntibodySystem Main Business
Table 132. AntibodySystem Latest Developments
Table 133. Antibodies.com Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 134. Antibodies.com Anti-GFP Nanobody Product Portfolios and Specifications
Table 135. Antibodies.com Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Antibodies.com Main Business
Table 137. Antibodies.com Latest Developments
Table 138. MBL Life Science Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 139. MBL Life Science Anti-GFP Nanobody Product Portfolios and Specifications
Table 140. MBL Life Science Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. MBL Life Science Main Business
Table 142. MBL Life Science Latest Developments
Table 143. Cosmo Bio Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 144. Cosmo Bio Anti-GFP Nanobody Product Portfolios and Specifications
Table 145. Cosmo Bio Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Cosmo Bio Main Business
Table 147. Cosmo Bio Latest Developments
Table 148. Bulldog Bio Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 149. Bulldog Bio Anti-GFP Nanobody Product Portfolios and Specifications
Table 150. Bulldog Bio Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Bulldog Bio Main Business
Table 152. Bulldog Bio Latest Developments
Table 153. System Biosciences Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 154. System Biosciences Anti-GFP Nanobody Product Portfolios and Specifications
Table 155. System Biosciences Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. System Biosciences Main Business
Table 157. System Biosciences Latest Developments
Table 158. Sino Biological Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 159. Sino Biological Anti-GFP Nanobody Product Portfolios and Specifications
Table 160. Sino Biological Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Sino Biological Main Business
Table 162. Sino Biological Latest Developments
Table 163. CUSABIO / Wuhan Huamei Biotech Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 164. CUSABIO / Wuhan Huamei Biotech Anti-GFP Nanobody Product Portfolios and Specifications
Table 165. CUSABIO / Wuhan Huamei Biotech Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. CUSABIO / Wuhan Huamei Biotech Main Business
Table 167. CUSABIO / Wuhan Huamei Biotech Latest Developments
Table 168. MSE Supplies Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 169. MSE Supplies Anti-GFP Nanobody Product Portfolios and Specifications
Table 170. MSE Supplies Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. MSE Supplies Main Business
Table 172. MSE Supplies Latest Developments
Table 173. KTSM Life Science Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 174. KTSM Life Science Anti-GFP Nanobody Product Portfolios and Specifications
Table 175. KTSM Life Science Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 176. KTSM Life Science Main Business
Table 177. KTSM Life Science Latest Developments
Table 1. Anti-GFP Nanobody Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Anti-GFP Nanobody Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monovalent Nanobodies
Table 4. Major Players of Bivalent Nanobodies
Table 5. Major Players of Bispecific Nanobodies
Table 6. Major Players of Multivalent Nanobodies
Table 7. Major Players of Fused Nanobodies
Table 8. Global Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 9. Global Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Table 10. Global Anti-GFP Nanobody Revenue by Type (2021-2026) & ($ million)
Table 11. Global Anti-GFP Nanobody Revenue Market Share by Type (2021-2026)
Table 12. Global Anti-GFP Nanobody Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Major Players of VHH Binding Protein
Table 14. Major Players of Affinity Gel / Resin
Table 15. Major Players of Magnetic Bead Reagent
Table 16. Major Players of Ready-to-Use IP Kit
Table 17. Global Anti-GFP Nanobody Sales by Reagent Format (2021-2026) & (K Units)
Table 18. Global Anti-GFP Nanobody Sales Market Share by Reagent Format (2021-2026)
Table 19. Global Anti-GFP Nanobody Revenue by Reagent Format (2021-2026) & ($ million)
Table 20. Global Anti-GFP Nanobody Revenue Market Share by Reagent Format (2021-2026)
Table 21. Global Anti-GFP Nanobody Sale Price by Reagent Format (2021-2026) & (US$/Unit)
Table 22. Major Players of Biotin-Conjugated Type
Table 23. Major Players of Fluorophore-Conjugated Type
Table 24. Major Players of HRP-Conjugated Type
Table 25. Major Players of Bead-Coupled Type
Table 26. Global Anti-GFP Nanobody Sales by Conjugation Type (2021-2026) & (K Units)
Table 27. Global Anti-GFP Nanobody Sales Market Share by Conjugation Type (2021-2026)
Table 28. Global Anti-GFP Nanobody Revenue by Conjugation Type (2021-2026) & ($ million)
Table 29. Global Anti-GFP Nanobody Revenue Market Share by Conjugation Type (2021-2026)
Table 30. Global Anti-GFP Nanobody Sale Price by Conjugation Type (2021-2026) & (US$/Unit)
Table 31. Global Anti-GFP Nanobody Sale by Application (2021-2026) & (K Units)
Table 32. Global Anti-GFP Nanobody Sale Market Share by Application (2021-2026)
Table 33. Global Anti-GFP Nanobody Revenue by Application (2021-2026) & ($ million)
Table 34. Global Anti-GFP Nanobody Revenue Market Share by Application (2021-2026)
Table 35. Global Anti-GFP Nanobody Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Anti-GFP Nanobody Sales by Company (2021-2026) & (K Units)
Table 37. Global Anti-GFP Nanobody Sales Market Share by Company (2021-2026)
Table 38. Global Anti-GFP Nanobody Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Anti-GFP Nanobody Revenue Market Share by Company (2021-2026)
Table 40. Global Anti-GFP Nanobody Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Anti-GFP Nanobody Producing Area Distribution and Sales Area
Table 42. Players Anti-GFP Nanobody Products Offered
Table 43. Anti-GFP Nanobody Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Anti-GFP Nanobody Sales by Geographic Region (2021-2026) & (K Units)
Table 47. Global Anti-GFP Nanobody Sales Market Share Geographic Region (2021-2026)
Table 48. Global Anti-GFP Nanobody Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Anti-GFP Nanobody Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Anti-GFP Nanobody Sales by Country/Region (2021-2026) & (K Units)
Table 51. Global Anti-GFP Nanobody Sales Market Share by Country/Region (2021-2026)
Table 52. Global Anti-GFP Nanobody Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Anti-GFP Nanobody Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Anti-GFP Nanobody Sales by Country (2021-2026) & (K Units)
Table 55. Americas Anti-GFP Nanobody Sales Market Share by Country (2021-2026)
Table 56. Americas Anti-GFP Nanobody Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 58. Americas Anti-GFP Nanobody Sales by Application (2021-2026) & (K Units)
Table 59. APAC Anti-GFP Nanobody Sales by Region (2021-2026) & (K Units)
Table 60. APAC Anti-GFP Nanobody Sales Market Share by Region (2021-2026)
Table 61. APAC Anti-GFP Nanobody Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 63. APAC Anti-GFP Nanobody Sales by Application (2021-2026) & (K Units)
Table 64. Europe Anti-GFP Nanobody Sales by Country (2021-2026) & (K Units)
Table 65. Europe Anti-GFP Nanobody Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 67. Europe Anti-GFP Nanobody Sales by Application (2021-2026) & (K Units)
Table 68. Middle East & Africa Anti-GFP Nanobody Sales by Country (2021-2026) & (K Units)
Table 69. Middle East & Africa Anti-GFP Nanobody Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Anti-GFP Nanobody Sales by Type (2021-2026) & (K Units)
Table 71. Middle East & Africa Anti-GFP Nanobody Sales by Application (2021-2026) & (K Units)
Table 72. Key Market Drivers & Growth Opportunities of Anti-GFP Nanobody
Table 73. Key Market Challenges & Risks of Anti-GFP Nanobody
Table 74. Key Industry Trends of Anti-GFP Nanobody
Table 75. Anti-GFP Nanobody Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Anti-GFP Nanobody Distributors List
Table 78. Anti-GFP Nanobody Customer List
Table 79. Global Anti-GFP Nanobody Sales Forecast by Region (2027-2032) & (K Units)
Table 80. Global Anti-GFP Nanobody Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Anti-GFP Nanobody Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Americas Anti-GFP Nanobody Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Anti-GFP Nanobody Sales Forecast by Region (2027-2032) & (K Units)
Table 84. APAC Anti-GFP Nanobody Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Anti-GFP Nanobody Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Europe Anti-GFP Nanobody Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Anti-GFP Nanobody Sales Forecast by Country (2027-2032) & (K Units)
Table 88. Middle East & Africa Anti-GFP Nanobody Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Anti-GFP Nanobody Sales Forecast by Type (2027-2032) & (K Units)
Table 90. Global Anti-GFP Nanobody Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Anti-GFP Nanobody Sales Forecast by Application (2027-2032) & (K Units)
Table 92. Global Anti-GFP Nanobody Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Proteintech / ChromoTek Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 94. Proteintech / ChromoTek Anti-GFP Nanobody Product Portfolios and Specifications
Table 95. Proteintech / ChromoTek Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Proteintech / ChromoTek Main Business
Table 97. Proteintech / ChromoTek Latest Developments
Table 98. Proteintech / ChromoTek GFP-Booster Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 99. Proteintech / ChromoTek GFP-Booster Anti-GFP Nanobody Product Portfolios and Specifications
Table 100. Proteintech / ChromoTek GFP-Booster Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Proteintech / ChromoTek GFP-Booster Main Business
Table 102. Proteintech / ChromoTek GFP-Booster Latest Developments
Table 103. NanoTag Biotechnologies Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 104. NanoTag Biotechnologies Anti-GFP Nanobody Product Portfolios and Specifications
Table 105. NanoTag Biotechnologies Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. NanoTag Biotechnologies Main Business
Table 107. NanoTag Biotechnologies Latest Developments
Table 108. NanoTag FluoTag-X4 anti-GFP Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 109. NanoTag FluoTag-X4 anti-GFP Anti-GFP Nanobody Product Portfolios and Specifications
Table 110. NanoTag FluoTag-X4 anti-GFP Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. NanoTag FluoTag-X4 anti-GFP Main Business
Table 112. NanoTag FluoTag-X4 anti-GFP Latest Developments
Table 113. BioLegend Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 114. BioLegend Anti-GFP Nanobody Product Portfolios and Specifications
Table 115. BioLegend Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. BioLegend Main Business
Table 117. BioLegend Latest Developments
Table 118. ABclonal Agarose Beads Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 119. ABclonal Agarose Beads Anti-GFP Nanobody Product Portfolios and Specifications
Table 120. ABclonal Agarose Beads Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. ABclonal Agarose Beads Main Business
Table 122. ABclonal Agarose Beads Latest Developments
Table 123. Yeasen Biotechnology Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 124. Yeasen Biotechnology Anti-GFP Nanobody Product Portfolios and Specifications
Table 125. Yeasen Biotechnology Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Yeasen Biotechnology Main Business
Table 127. Yeasen Biotechnology Latest Developments
Table 128. AntibodySystem Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 129. AntibodySystem Anti-GFP Nanobody Product Portfolios and Specifications
Table 130. AntibodySystem Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. AntibodySystem Main Business
Table 132. AntibodySystem Latest Developments
Table 133. Antibodies.com Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 134. Antibodies.com Anti-GFP Nanobody Product Portfolios and Specifications
Table 135. Antibodies.com Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Antibodies.com Main Business
Table 137. Antibodies.com Latest Developments
Table 138. MBL Life Science Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 139. MBL Life Science Anti-GFP Nanobody Product Portfolios and Specifications
Table 140. MBL Life Science Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. MBL Life Science Main Business
Table 142. MBL Life Science Latest Developments
Table 143. Cosmo Bio Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 144. Cosmo Bio Anti-GFP Nanobody Product Portfolios and Specifications
Table 145. Cosmo Bio Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Cosmo Bio Main Business
Table 147. Cosmo Bio Latest Developments
Table 148. Bulldog Bio Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 149. Bulldog Bio Anti-GFP Nanobody Product Portfolios and Specifications
Table 150. Bulldog Bio Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Bulldog Bio Main Business
Table 152. Bulldog Bio Latest Developments
Table 153. System Biosciences Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 154. System Biosciences Anti-GFP Nanobody Product Portfolios and Specifications
Table 155. System Biosciences Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. System Biosciences Main Business
Table 157. System Biosciences Latest Developments
Table 158. Sino Biological Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 159. Sino Biological Anti-GFP Nanobody Product Portfolios and Specifications
Table 160. Sino Biological Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Sino Biological Main Business
Table 162. Sino Biological Latest Developments
Table 163. CUSABIO / Wuhan Huamei Biotech Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 164. CUSABIO / Wuhan Huamei Biotech Anti-GFP Nanobody Product Portfolios and Specifications
Table 165. CUSABIO / Wuhan Huamei Biotech Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. CUSABIO / Wuhan Huamei Biotech Main Business
Table 167. CUSABIO / Wuhan Huamei Biotech Latest Developments
Table 168. MSE Supplies Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 169. MSE Supplies Anti-GFP Nanobody Product Portfolios and Specifications
Table 170. MSE Supplies Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. MSE Supplies Main Business
Table 172. MSE Supplies Latest Developments
Table 173. KTSM Life Science Basic Information, Anti-GFP Nanobody Manufacturing Base, Sales Area and Its Competitors
Table 174. KTSM Life Science Anti-GFP Nanobody Product Portfolios and Specifications
Table 175. KTSM Life Science Anti-GFP Nanobody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 176. KTSM Life Science Main Business
Table 177. KTSM Life Science Latest Developments
LIST OF FIGURES
Figure 1. Picture of Anti-GFP Nanobody
Figure 2. Anti-GFP Nanobody Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-GFP Nanobody Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Anti-GFP Nanobody Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Anti-GFP Nanobody Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Anti-GFP Nanobody Sales Market Share by Country/Region (2025)
Figure 10. Anti-GFP Nanobody Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Monovalent Nanobodies
Figure 12. Product Picture of Bivalent Nanobodies
Figure 13. Product Picture of Bispecific Nanobodies
Figure 14. Product Picture of Multivalent Nanobodies
Figure 15. Product Picture of Fused Nanobodies
Figure 16. Global Anti-GFP Nanobody Sales Market Share by Type in 2026
Figure 17. Global Anti-GFP Nanobody Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of VHH Binding Protein
Figure 19. Product Picture of Affinity Gel / Resin
Figure 20. Product Picture of Magnetic Bead Reagent
Figure 21. Product Picture of Ready-to-Use IP Kit
Figure 22. Global Anti-GFP Nanobody Sales Market Share by Reagent Format in 2026
Figure 23. Global Anti-GFP Nanobody Revenue Market Share by Reagent Format (2021-2026)
Figure 24. Product Picture of Biotin-Conjugated Type
Figure 25. Product Picture of Fluorophore-Conjugated Type
Figure 26. Product Picture of HRP-Conjugated Type
Figure 27. Product Picture of Bead-Coupled Type
Figure 28. Global Anti-GFP Nanobody Sales Market Share by Conjugation Type in 2026
Figure 29. Global Anti-GFP Nanobody Revenue Market Share by Conjugation Type (2021-2026)
Figure 30. Anti-GFP Nanobody Consumed in University Laboratory
Figure 31. Global Anti-GFP Nanobody Market: University Laboratory (2021-2026) & (K Units)
Figure 32. Anti-GFP Nanobody Consumed in Research Institute
Figure 33. Global Anti-GFP Nanobody Market: Research Institute (2021-2026) & (K Units)
Figure 34. Anti-GFP Nanobody Consumed in Biotechnology Company
Figure 35. Global Anti-GFP Nanobody Market: Biotechnology Company (2021-2026) & (K Units)
Figure 36. Anti-GFP Nanobody Consumed in Pharmaceutical R&D Lab
Figure 37. Global Anti-GFP Nanobody Market: Pharmaceutical R&D Lab (2021-2026) & (K Units)
Figure 38. Global Anti-GFP Nanobody Sale Market Share by Application (2025)
Figure 39. Global Anti-GFP Nanobody Revenue Market Share by Application in 2025
Figure 40. Anti-GFP Nanobody Sales by Company in 2025 (K Units)
Figure 41. Global Anti-GFP Nanobody Sales Market Share by Company in 2025
Figure 42. Anti-GFP Nanobody Revenue by Company in 2025 ($ millions)
Figure 43. Global Anti-GFP Nanobody Revenue Market Share by Company in 2025
Figure 44. Global Anti-GFP Nanobody Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global Anti-GFP Nanobody Revenue Market Share by Geographic Region in 2025
Figure 46. Americas Anti-GFP Nanobody Sales 2021-2026 (K Units)
Figure 47. Americas Anti-GFP Nanobody Revenue 2021-2026 ($ millions)
Figure 48. APAC Anti-GFP Nanobody Sales 2021-2026 (K Units)
Figure 49. APAC Anti-GFP Nanobody Revenue 2021-2026 ($ millions)
Figure 50. Europe Anti-GFP Nanobody Sales 2021-2026 (K Units)
Figure 51. Europe Anti-GFP Nanobody Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa Anti-GFP Nanobody Sales 2021-2026 (K Units)
Figure 53. Middle East & Africa Anti-GFP Nanobody Revenue 2021-2026 ($ millions)
Figure 54. Americas Anti-GFP Nanobody Sales Market Share by Country in 2025
Figure 55. Americas Anti-GFP Nanobody Revenue Market Share by Country (2021-2026)
Figure 56. Americas Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Figure 57. Americas Anti-GFP Nanobody Sales Market Share by Application (2021-2026)
Figure 58. United States Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC Anti-GFP Nanobody Sales Market Share by Region in 2025
Figure 63. APAC Anti-GFP Nanobody Revenue Market Share by Region (2021-2026)
Figure 64. APAC Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Figure 65. APAC Anti-GFP Nanobody Sales Market Share by Application (2021-2026)
Figure 66. China Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 70. India Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe Anti-GFP Nanobody Sales Market Share by Country in 2025
Figure 74. Europe Anti-GFP Nanobody Revenue Market Share by Country (2021-2026)
Figure 75. Europe Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Figure 76. Europe Anti-GFP Nanobody Sales Market Share by Application (2021-2026)
Figure 77. Germany Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 78. France Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 79. UK Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa Anti-GFP Nanobody Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa Anti-GFP Nanobody Sales Market Share by Application (2021-2026)
Figure 85. Egypt Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of Anti-GFP Nanobody in 2026
Figure 91. Manufacturing Process Analysis of Anti-GFP Nanobody
Figure 92. Industry Chain Structure of Anti-GFP Nanobody
Figure 93. Channels of Distribution
Figure 94. Global Anti-GFP Nanobody Sales Market Forecast by Region (2027-2032)
Figure 95. Global Anti-GFP Nanobody Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global Anti-GFP Nanobody Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global Anti-GFP Nanobody Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global Anti-GFP Nanobody Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global Anti-GFP Nanobody Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Anti-GFP Nanobody
Figure 2. Anti-GFP Nanobody Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-GFP Nanobody Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Anti-GFP Nanobody Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Anti-GFP Nanobody Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Anti-GFP Nanobody Sales Market Share by Country/Region (2025)
Figure 10. Anti-GFP Nanobody Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Monovalent Nanobodies
Figure 12. Product Picture of Bivalent Nanobodies
Figure 13. Product Picture of Bispecific Nanobodies
Figure 14. Product Picture of Multivalent Nanobodies
Figure 15. Product Picture of Fused Nanobodies
Figure 16. Global Anti-GFP Nanobody Sales Market Share by Type in 2026
Figure 17. Global Anti-GFP Nanobody Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of VHH Binding Protein
Figure 19. Product Picture of Affinity Gel / Resin
Figure 20. Product Picture of Magnetic Bead Reagent
Figure 21. Product Picture of Ready-to-Use IP Kit
Figure 22. Global Anti-GFP Nanobody Sales Market Share by Reagent Format in 2026
Figure 23. Global Anti-GFP Nanobody Revenue Market Share by Reagent Format (2021-2026)
Figure 24. Product Picture of Biotin-Conjugated Type
Figure 25. Product Picture of Fluorophore-Conjugated Type
Figure 26. Product Picture of HRP-Conjugated Type
Figure 27. Product Picture of Bead-Coupled Type
Figure 28. Global Anti-GFP Nanobody Sales Market Share by Conjugation Type in 2026
Figure 29. Global Anti-GFP Nanobody Revenue Market Share by Conjugation Type (2021-2026)
Figure 30. Anti-GFP Nanobody Consumed in University Laboratory
Figure 31. Global Anti-GFP Nanobody Market: University Laboratory (2021-2026) & (K Units)
Figure 32. Anti-GFP Nanobody Consumed in Research Institute
Figure 33. Global Anti-GFP Nanobody Market: Research Institute (2021-2026) & (K Units)
Figure 34. Anti-GFP Nanobody Consumed in Biotechnology Company
Figure 35. Global Anti-GFP Nanobody Market: Biotechnology Company (2021-2026) & (K Units)
Figure 36. Anti-GFP Nanobody Consumed in Pharmaceutical R&D Lab
Figure 37. Global Anti-GFP Nanobody Market: Pharmaceutical R&D Lab (2021-2026) & (K Units)
Figure 38. Global Anti-GFP Nanobody Sale Market Share by Application (2025)
Figure 39. Global Anti-GFP Nanobody Revenue Market Share by Application in 2025
Figure 40. Anti-GFP Nanobody Sales by Company in 2025 (K Units)
Figure 41. Global Anti-GFP Nanobody Sales Market Share by Company in 2025
Figure 42. Anti-GFP Nanobody Revenue by Company in 2025 ($ millions)
Figure 43. Global Anti-GFP Nanobody Revenue Market Share by Company in 2025
Figure 44. Global Anti-GFP Nanobody Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global Anti-GFP Nanobody Revenue Market Share by Geographic Region in 2025
Figure 46. Americas Anti-GFP Nanobody Sales 2021-2026 (K Units)
Figure 47. Americas Anti-GFP Nanobody Revenue 2021-2026 ($ millions)
Figure 48. APAC Anti-GFP Nanobody Sales 2021-2026 (K Units)
Figure 49. APAC Anti-GFP Nanobody Revenue 2021-2026 ($ millions)
Figure 50. Europe Anti-GFP Nanobody Sales 2021-2026 (K Units)
Figure 51. Europe Anti-GFP Nanobody Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa Anti-GFP Nanobody Sales 2021-2026 (K Units)
Figure 53. Middle East & Africa Anti-GFP Nanobody Revenue 2021-2026 ($ millions)
Figure 54. Americas Anti-GFP Nanobody Sales Market Share by Country in 2025
Figure 55. Americas Anti-GFP Nanobody Revenue Market Share by Country (2021-2026)
Figure 56. Americas Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Figure 57. Americas Anti-GFP Nanobody Sales Market Share by Application (2021-2026)
Figure 58. United States Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC Anti-GFP Nanobody Sales Market Share by Region in 2025
Figure 63. APAC Anti-GFP Nanobody Revenue Market Share by Region (2021-2026)
Figure 64. APAC Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Figure 65. APAC Anti-GFP Nanobody Sales Market Share by Application (2021-2026)
Figure 66. China Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 70. India Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe Anti-GFP Nanobody Sales Market Share by Country in 2025
Figure 74. Europe Anti-GFP Nanobody Revenue Market Share by Country (2021-2026)
Figure 75. Europe Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Figure 76. Europe Anti-GFP Nanobody Sales Market Share by Application (2021-2026)
Figure 77. Germany Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 78. France Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 79. UK Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa Anti-GFP Nanobody Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa Anti-GFP Nanobody Sales Market Share by Application (2021-2026)
Figure 85. Egypt Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries Anti-GFP Nanobody Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of Anti-GFP Nanobody in 2026
Figure 91. Manufacturing Process Analysis of Anti-GFP Nanobody
Figure 92. Industry Chain Structure of Anti-GFP Nanobody
Figure 93. Channels of Distribution
Figure 94. Global Anti-GFP Nanobody Sales Market Forecast by Region (2027-2032)
Figure 95. Global Anti-GFP Nanobody Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global Anti-GFP Nanobody Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global Anti-GFP Nanobody Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global Anti-GFP Nanobody Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global Anti-GFP Nanobody Revenue Market Share Forecast by Application (2027-2032)
